Acarix A/S

Acarix A/S specializes in the development of innovative diagnostic solutions for cardiovascular diseases, utilizing advanced acoustic technology to enhance clinical decision-making and patient care. Founded in 2009 in Denmark, Acarix A/S focuses on providing groundbreaking diagnostic tools for cardiac conditions. The company has not undergone any significant changes in its business strategy since its inception. Samuel Schmidt founded the company, and it raised EUR 3.

60 mn in its most recent funding round on November 7, 2016, led by SEED Capital, bringing the total amount raised to EUR 3. 60 mn. Acarix A/S primarily offers a diagnostic system that leverages acoustic technology to aid in the identification of coronary artery disease. This system is designed for use in clinical settings, facilitating early detection and improving patient outcomes.

Its products cater to healthcare providers aiming to enhance diagnostic accuracy and patient management in cardiology, with a focus on a global market presence across Europe and North America. The revenue model for Acarix A/S is based on sales of its diagnostic systems and related services to healthcare providers. The company reported an EBITDA amount of EUR -2,964,771 for the most recent year, 2023, indicating operational challenges that may impact future financial performance. Acarix A/S plans to expand its product line by introducing enhanced versions of its diagnostic systems and additional features aimed at improving user experience and clinical outcomes.

The company is targeting markets in North America and Asia for expansion by 2025. The funds raised in the recent investment will be utilized to support these initiatives, including product development and market entry strategies.